Frontiers in Pharmacology (Apr 2022)

ING4 Promotes Stemness Enrichment of Human Renal Cell Carcinoma Cells Through Inhibiting DUSP4 Expression to Activate the p38 MAPK/type I IFN-Stimulated Gene Signaling Pathway

  • Yu Tang,
  • Yu Tang,
  • Xinyue Yang,
  • Xinyue Yang,
  • Qing Wang,
  • Qing Wang,
  • Haoyu Huang,
  • Haoyu Huang,
  • Qinzhi Wang,
  • Qinzhi Wang,
  • Min Jiang,
  • Min Jiang,
  • Chunluan Yuan,
  • Yefei Huang,
  • Yefei Huang,
  • Yansu Chen,
  • Yansu Chen

DOI
https://doi.org/10.3389/fphar.2022.845097
Journal volume & issue
Vol. 13

Abstract

Read online

Renal cell carcinoma (RCC) recurs frequently due to high metastatic spread, resulting in a high mortality. Cancer stem cells play a critical role in initiating the tumor metastasis. Inhibitor of growth 4 (ING4) is a member of the ING family, but its impact on cancer stem cells in RCC is still unknown. In this study, we found that ING4 significantly promoted the sphere-forming size and number of RCC cells under an ultralow-attachment culture condition in vitro, tumor growth and metastasis in vivo, and the expression of some stem-like or pluripotent biomarkers CD44, MYC, OCT4, and NANOG, indicating that ING4 increased the stemness enrichment of RCC cells. Mechanistically, the ING4-activated p38 MAPK pathway possibly upregulated the expression of type I IFN-stimulated genes to promote the formation of RCC stem cells. ING4 could inhibit the expression of DUSP4 to activate p38 MAPK. In addition, selective pharmacological p38 MAPK inhibitors could significantly inhibit stemness enrichment only in ING4-overexpressed RCC cells, suggesting that the p38 MAPK inhibitors might be effective in patients with high ING4 expression in RCC tissue. Taken together, our findings proposed that ING4 might serve as a potential therapeutic target for metastatic RCC, particularly RCC stem cells.

Keywords